TELA Bio Appoints Roberto Cuca as Chief Operating Officer and Chief Financial Officer

$TELA
Medical/Dental Instruments
Health Care
Get the next $TELA alert in real time by email

MALVERN, Pa., Sept. 27, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the appointment of Roberto Cuca as the Company's new Chief Operating Officer (COO) and Chief Financial Officer (CFO). As COO and CFO, Roberto Cuca will lead the execution of the Company's business plan and manage the Company's finances. He will report directly to President and Chief Executive Officer, Antony Koblish.

Roberto Cuca joins the TELA team with over 25 years of experience in relevant operational and finance positions within the healthcare industry. Most recently, Mr. Cuca served as Chief Financial Officer of OraSure Technologies, a point-of-care testing and sample collection technologies company, where he led the finance and IT functions since joining in 2018. Prior to that time, Mr. Cuca served as Senior Vice President and Chief Financial Officer of Trevana, Inc., a clinical-stage biopharmaceutical company, where he led the finance and investor relations functions and worked with senior management to establish and execute overall corporate strategy. Prior to his time with Trevana, Mr. Cuca held various leadership positions within the finance organization of Endo Health Solutions Inc., a pharmaceutical company, including Treasurer and Senior Vice President, Finance, where he was responsible for capital raises and cash management, mergers, acquisitions and licensing transactions, tax planning and compliance, and risk management. Mr. Cuca received an M.B.A from the Wharton School of the University of Pennsylvania, a J.D. from Cornell Law School, and an A.B. from Princeton University. Mr. Cuca is also a CFA Charterholder.

"I am delighted to welcome Roberto to the TELA Bio team. We are privileged to have such a talented professional joining us in the COO and CFO roles. We have built a solid team to date and are pleased to be adding further strength at the executive level," said Antony Koblish, President and CEO of TELA Bio. "His extensive operational and financial experience, along with a proven track record of execution, will be a valuable addition to TELA."

"I'm thrilled to join TELA Bio and to contribute to a company making significant advancements in soft tissue reinforcement and reconstruction," said Roberto Cuca, COO and CFO of TELA Bio. "I look forward to working with Tony and the entire organization, bringing my knowledge and experience to bear on the execution of TELA's business plan and strategy and driving continued growth."

On September 27, 2021, in connection with Mr. Cuca's appointment as COO and CFO and in accordance with the terms of an employment agreement between Mr. Cuca and TELA, the Board of Directors granted Mr. Cuca an option to purchase 144,000 shares of TELA's common stock, with an exercise price equal to the closing price of TELA's common stock on the NASDAQ Global Market on September 27, 2021. The option was granted as an inducement material to his acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments thereafter. The vesting of the option is subject to Mr. Cuca's continued service with the Company.

About TELA Bio, Inc.

TELA Bio Inc. (NASDAQ:TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements



This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact

Greg Chodaczek

347-620-7010 

ir@telabio.com



Primary Logo

Get the next $TELA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TELA

DatePrice TargetRatingAnalyst
3/21/2025$5.00 → $2.00Overweight → Neutral
Piper Sandler
5/31/2022$17.00Buy
Lake Street
More analyst ratings

$TELA
Press Releases

Fastest customizable press release news feed in the world

See more
  • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his

    $TELA
    Medical/Dental Instruments
    Health Care

$TELA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TELA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TELA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TELA
SEC Filings

See more

$TELA
Leadership Updates

Live Leadership Updates

See more
  • TELA Bio Appoints Jeffrey Blizard to its Board of Directors

    MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff join our Board as we continue to develop and optimize our sales force," said Antony Koblish, co-founder, President and Chief Executive Officer of TELA Bio. "Jeff's exceptional sales leader

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio Appoints Greg Firestone as Chief Commercial Officer

    MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbursement strategy across the Company's product lines. "Greg has been an instrumental player in the TELA Bio story, supporting our commercial strategy and cultivating each of our key group

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

    MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced Howard N. Langstein, MD, FACS, as Vice President of Medical Affairs and Surgeon Strategy. Dr. Langstein is the former Chief of Plastic and Reconstructive Surgery at the University of Rochester Medical Center, known for his extensive expertise, especially in microvascular reconstruction and innovative approaches to complex surgical problems. Dr. Langstein previously held the position of Associate Professor of Plastic Surgery at the University of Texas MD Anderson Cancer Center, where

    $TELA
    Medical/Dental Instruments
    Health Care

$TELA
Financials

Live finance-specific insights

See more
  • TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, r

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results

    MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15

    $TELA
    Medical/Dental Instruments
    Health Care
  • TELA Bio to Announce Third Quarter 2024 Financial Results

    MALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ:TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2024 financial results on Thursday, November 7, 2024. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Third Quarter Earnings Conference Call and Webcast DetailsInvestors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before

    $TELA
    Medical/Dental Instruments
    Health Care

$TELA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more